RxDoctor Payments DataLook up a doctor →

Troy Weirick, MD

Cardiovascular Disease · Elkhart, INNPI 1679717771

Payments from drug & device makers

$373,652in general payments, 2019–2025

Across 1,017 payments — averaging $367.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$132K
  • Esperion Therapeutics, Inc.$103K
  • Novartis$84K
  • Amgen$22K
  • AstraZeneca$21K
  • Johnson & Johnson$1K
  • plus $11K from 45 others

What the payments were for

  • Travel & lodging$4353%
  • Food & beverage$15,37397%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$373,652 in reported general payments places this provider in the 95th percentile of 408 cardiovascular disease providers in Indiana.

See all cardiovascular disease providers in Indiana

Medicare billing

Part B allowed, 2024
$265,722
Medicare patients
964
Services billed
3,395

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban571$618,883
EntrestoSacubitril/Valsartan238$277,113
XareltoRivaroxaban160$182,972
JardianceEmpagliflozin130$150,565
Repatha SureclickEvolocumab134$138,166
BrilintaTicagrelor73$72,475
FarxigaDapagliflozin Propanediol60$57,898
MultaqDronedarone Hcl30$46,923
VascepaIcosapent Ethyl29$27,721
Ranolazine ErRanolazine106$22,493
Praluent PenAlirocumab19$21,181
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$8,385
Dabigatran EtexilateDabigatran Etexilate Mesylate29$8,189
Atorvastatin Calcium1,116$7,670
Ezetimibe390$7,122

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$532$618,883571 claims
NovartisEntresto$83,645$277,113238 claims
Johnson & JohnsonXarelto$1,276$182,972160 claims
Boehringer IngelheimJardiance$514$150,565130 claims
AstraZenecaBrilinta, Farxiga$20,993$130,372133 claims
Sanofi-aventis U.S. LLCMultaq$274$46,92330 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 408 cardiovascular disease providers in Indiana.

Other cardiovascular disease in Elkhart

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →